381 related articles for article (PubMed ID: 25646413)
21. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
D'Abundo L; Callegari E; Bresin A; Chillemi A; Elamin BK; Guerriero P; Huang X; Saccenti E; Hussein EMAA; Casciano F; Secchiero P; Zauli G; Calin GA; Russo G; Lee LJ; Croce CM; Marcucci G; Sabbioni S; Malavasi F; Negrini M
Oncogene; 2017 Nov; 36(47):6617-6626. PubMed ID: 28783166
[TBL] [Abstract][Full Text] [Related]
22. Chronic lymphocytic leukemia: molecular genetics and animal models.
Pekarsky Y; Calin GA; Aqeilan R
Curr Top Microbiol Immunol; 2005; 294():51-70. PubMed ID: 16323427
[TBL] [Abstract][Full Text] [Related]
23. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
24. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
[TBL] [Abstract][Full Text] [Related]
25. A large fraction of trisomy 12, 17p
Pepe F; Rassenti LZ; Pekarsky Y; Labanowska J; Nakamura T; Nigita G; Kipps TJ; Balatti V; Croce CM
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064090
[TBL] [Abstract][Full Text] [Related]
26. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.
Yang YQ; Tian T; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Wang L; Fan L; Li JY; Xu W
BMC Cancer; 2018 Oct; 18(1):1009. PubMed ID: 30348117
[TBL] [Abstract][Full Text] [Related]
27. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
28. The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia.
Tari K; Shamsi Z; Reza Ghafari H; Atashi A; Shahjahani M; Abroun S
Exp Oncol; 2018 Dec; 40(4):261-267. PubMed ID: 30593759
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.
Mraz M; Pospisilova S; Malinova K; Slapak I; Mayer J
Leuk Lymphoma; 2009 Mar; 50(3):506-9. PubMed ID: 19347736
[TBL] [Abstract][Full Text] [Related]
30. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
31. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
[TBL] [Abstract][Full Text] [Related]
32. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
[TBL] [Abstract][Full Text] [Related]
33. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.
Liu J; Chen G; Pelicano H; Liao J; Huang J; Feng L; Keating MJ; Huang P
Oncotarget; 2016 Nov; 7(44):71378-71389. PubMed ID: 27655686
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
35. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
[TBL] [Abstract][Full Text] [Related]
36. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
[TBL] [Abstract][Full Text] [Related]
37. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.
Blume CJ; Hotz-Wagenblatt A; Hüllein J; Sellner L; Jethwa A; Stolz T; Slabicki M; Lee K; Sharathchandra A; Benner A; Dietrich S; Oakes CC; Dreger P; te Raa D; Kater AP; Jauch A; Merkel O; Oren M; Hielscher T; Zenz T
Leukemia; 2015 Oct; 29(10):2015-23. PubMed ID: 25971364
[TBL] [Abstract][Full Text] [Related]
38. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
39. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
Braga TV; Evangelista FCG; Gomes LC; Araújo SSDS; Carvalho MDG; Sabino AP
Biomed Pharmacother; 2017 Aug; 92():864-869. PubMed ID: 28599250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
